Valion Bio, Inc. carries no debt; cash flow comfortably covers obligations.

Valion Bio, Inc. has insufficient data to evaluate this check.

Valion Bio, Inc. has insufficient data to evaluate this check.

Valion Bio, Inc. has insufficient data to evaluate this check.

Valion Bio, Inc. has a net cash position, so leverage is healthy.

Valion Bio, Inc. carries no debt; interest obligations are fully covered.

Valion Bio, Inc. has insufficient data to evaluate this check.

Valion Bio, Inc. has insufficient data to evaluate this check.

Valion Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Valion Bio, Inc.'s return on equity of -18.83%, is lower than 15.00%, indicating bad performance

Valion Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Valion Bio, Inc. has insufficient public price history to evaluate earnings stability.

Valion Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Valion Bio, Inc. has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Valion Bio, Inc.'s yearly earnings has increased -79.82% since last year from $-4.37M to $-880.85K, signaling increasing performance

Valion Bio, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -2.07% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Valion Bio, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Valion Bio, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Valion Bio, Inc. has insufficient public price history to evaluate ROE consistency.

Valion Bio, Inc. has insufficient data to evaluate this check.

Valion Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Valion Bio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Valion Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Valion Bio, Inc. has insufficient data to evaluate this check.

Valion Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Valion Bio, Inc. has a price-to-book ratio of 0.96x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Valion Bio, Inc. has a price-to-sales ratio of 19.07x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue